**Supplemental Fig. S1. Kaplan-Meier curves of MALAT-1 expression and OS/RFS in different cancers.**
**(A)** The relationship between MALAT-1 and OS is shown; **(B)** The relationship between MALAT-1 and RFS is shown. According to the calculated HR and a 95%CI in different cancers, lncRNA was set at a ≥1.5-fold difference. The false discovery ratio (FDR) was < 0.05.


**Supplemental Fig. S2. Funnel plot analysis of potential publication bias for OS/RFS.**
**(A)** There were no significant publication biases for OS (Egg's test: P>|t|=0.064>0.05, Begg's test: Pr>|z|=0.554); **(B)** There were no significant publication biases for RFS (Begg's test: Pr>|z|=0.260, Egg's test: P>|t|=0.656>0.05).

# Supplemental Fig. S1. A

**GSE10846 DLBCL OS**

Deaths/N
Low 106/177
High 59/237

*p*<0.0001
HR=0.461

**GSE11318 DLBCL OS**

*p*=0.0424
HR=0.465

Deaths/N
Low 107/186
High 5/14

**GSE23501 DLBCL OS**

*p*=0.0328
HR=0.223

Deaths/N
Low 11/38
High 2/31

**GSE22762 Lymphocytic Leukemia OS**

*p*<0.0001
HR=2.781

Deaths/N
Low 1/18
High 24/70

**GSE18520 Ovarian Cancer OS**

Deaths/N
Low 1/3
High 40/50

*p*=0.2535
HR=4.763

**GSE19829 Ovarian Cancer OS**

Deaths/N
Low 14/25
High 3/3

*p*=0.0597
HR=3.153

**GSE30161 Ovarian Cancer OS**

*p*=0.0498
HR=5.847

Deaths/N
Low 4/11
High 35/54

**GSE20711 Breast Cancer OS**

*p*=0.0239
HR=7.208

Deaths/N
Low 1/18
High 3/3

# Supplemental Fig. S1. A

### GSE31210 Lung Cancer OS

Proportion of Patients

Deaths/N
Low 30/213
High 5/13

*p*=0.0167
HR=3.009

Months from Start of Therapy

### GSE29013 Lung Cancer OS

Proportion of Patients

*p*=0.911
HR=1.189

Deaths/N
Low 11/33
High 7/22

Months from Start of Therapy

### GSE37745 Lung Cancer OS

Proportion of Patients

Deaths/N
Low 51/74
High 94/122

*p*=0.2250
HR=0.809

Months from Start of Therapy

### GSE50081 Lung Cancer OS

Proportion of Patients

*p*=0.0261
HR=1.964

Deaths/N
Low 6/26
High 69/155

Months from Start of Therapy

### GSE16581 Meningiomas OS

Proportion of Patients

*p*=0.0185
HR=0.274

Deaths/N
Low 8/38
High 2/29

Months from Start of Therapy

### GSE7696 Glioblastoma OS

Proportion of Patients

Deaths/N
Low 14/20
High 51/60

*p*=0.0197
HR=2.032

Months from Start of Therapy

### GSE19234 Melanoma OS

Proportion of Patients

*p*=0.2799
HR=0.348

Deaths/N
Low 22/44
High 2/3

Months from Start of Therapy

### GSE12417 CN-AML OS

Proportion of Patients

*p*=0.0029
HR=3.488

Deaths/N
Low 41/73
High 6/6

Months from Start of Therapy

# Supplemental Fig. S1. B



GSE6532 Breast Cancer RFS



GSE9195 Breast Cancer RFS



GSE20711 Breast Cancer RFS



GSE 31595 Colon Cancer RFS



GSE37745 Lung Cancer RFS

# Fig. S2

**A**

Begg's funnel plot with pseudo 95% confidence limits



**B**

Begg's funnel plot with pseudo 95% confidence limits